Results 81 to 90 of about 47,249 (313)

An Aggregation‐Induced Polymerization Poly(Disulfide)‐Drug Nanoplatform for Autoimmune Uveitis Therapy via Inhibiting the cGAS‐STING Pathway

Advanced Science, EarlyView.
A cationic poly(disulfide)‐drug nanoplatform (LA/DexP) was developed to treat experimental autoimmune uveitis (EAU). With potent blood‐retinal barrier penetrability, LA/DexP releases DSP in response to high ROS and scavenges cfDNA to inhibit the cGAS‐STING signaling pathway.
Yuelan Wu, Wenbo Geng, Qinjin Dai, Wanyun Zhang, Yuxian Lai, Pei Zhang, Chunjiang Zhou, Yinuo Wang, Qingfeng Cao, Xiang Luo, Yujie Lai, Changwei Huang, Peizeng Yang   +12 more
wiley   +1 more source

Pulmonary Infections with Nontuberculous Mycobacteria, Catalonia, Spain, 1994–2014

Emerging Infectious Diseases, 2018
In Spain, systematic reporting of pulmonary infections with nontuberculous mycobacteria is not mandatory. Therefore, to determine trends, we retrospectively identified cases for January 1994–December 2014 in Catalonia.
Miguel Santin, Irene Barrabeig, Pierre Malchair, Lucia Gonzalez-Luquero, Miguel A. Benitez, Josefina Sabria, Merce Palau-Benavent, Concepcion Cañete, Joan A. Lloret-Queraltó, Maria D. Grijota-Camino, Jordi Dorca, Fernando Alcaide   +11 more
doaj   +1 more source

Accelerating Primary Screening of USP8 Inhibitors from Drug Repurposing Databases with Tree‐Based Machine Learning

Advanced Intelligent Discovery, EarlyView.
This study introduces a tree‐based machine learning approach to accelerate USP8 inhibitor discovery. The best‐performing model identified 100 high‐confidence repurposable compounds, half already approved or in clinical trials, and uncovered novel scaffolds not previously studied. These findings offer a solid foundation for rapid experimental follow‐up,
Yik Kwong Ng, Sharon Ai Er Lam, Wei Chun Lim, Hannah Hui Min Toh, Shi Jun Ang   +4 more
wiley   +1 more source

Mycobacterium conceptionense Pneumonitis in Patient with HIV/AIDS

Emerging Infectious Diseases, 2019
Approximately 21 human cases of infection with Mycobacterium conceptionense have been reported. However, most cases were outside the United States, and optimal treatment remains uncertain. We report a case of M.
Sarah M. Michienzi, Rodrigo M. Burgos, Richard M. Novak   +2 more
doaj   +1 more source

Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single‐Arm Clinical Trial

Annals of Neurology, EarlyView.
Objective To evaluate the effectiveness and safety of ocrelizumab in self‐identified black and Hispanic people with relapsing multiple sclerosis. Methods The Characterization of Ocrelizumab in Minorities with Multiple Sclerosis (CHIMES) trial, a prospective, open‐label, single‐arm, phase 4 study, intentionally recruited underrepresented populations in ...
Lilyana Amezcua, Anthony T. Reder, Evanthia Bernitsas, Nancy L. Monson, Timothy Vartanian, Gregory F. Wu, Mansoor Saleh, Annette Okai, Ahmed Z. Obeidat, Dilraj Sokhi, Rikisha Parekh, Jinglan Pei, Christopher Harp, David Clayton, Ibraheem Abioye, Mitzi J. Williams, for the CHIMES Study Group   +16 more
wiley   +1 more source

VapC Toxins from Mycobacterium tuberculosis are ribonucleases that differentially inhibit growth and are neutralized by cognate VapB antitoxins [PDF]

, 2011
The chromosome of Mycobacterium tuberculosis (Mtb) encodes forty seven toxin-antitoxin modules belonging to the VapBC family. The role of these modules in the physiology of Mtb and the function(s) served by their expansion are unknown.
Mizrahi, Valerie, Bhavna G Gordhan, Vickery Arcus, Diane Kuhnert, Valerie Mizrahi, Ahidjo, Bintou Ahmadou, Kuhnert, Diane, Edith E Machowski, Machowski E.E., Joanna L. Mckenzie, Garth L. Abrahams, Kuhnert D., Machowski Edith E., Abrahams, Garth L., Ahidjo B.A., Bintou Ahmadou Ahidjo, Gordhan, Bhavna G., Arcus V., Garth L Abrahams, Abrahams G.L., Machowski, Edith E., Mizrahi V., Kuhnert Diane, Ahidjo Bintou Ahmadou, McKenzie Joanna L., Arcus Vickery, Mizrahi Valerie, Edith E. Machowski, Abrahams Garth L., Gordhan B.G., McKenzie J.L., Gordhan Bhavna G., Bhavna G, Arcus, Vickery L., Bhavna G. Gordhan, McKenzie, Joanna Leigh, Joanna L McKenzie   +36 more
core   +1 more source

Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011–2015

Emerging Infectious Diseases, 2018
We used tuberculosis genotyping results to derive estimates of prevalence of latent tuberculosis infection in the United States. We estimated
Maryam B. Haddad, Kala M. Raz, Timothy L. Lash, Andrew N. Hill, J. Steve Kammerer, Carla A. Winston, Kenneth G. Castro, Neel R. Gandhi, Thomas R. Navin   +8 more
doaj   +1 more source

Rewriting Tumor Immunity With Bacterial Membrane Vesicles: A Versatile and Potent Therapeutic Strategy

Advanced NanoBiomed Research, EarlyView.
Bacterial membrane vesicles (BMVs) emerge as promising platforms for cancer immunotherapy owing to their intrinsic adjuvant properties and tunable cargo delivery capabilities. Their ability to modulate the tumor microenvironment, enhance antitumor immune responses, and support personalized therapeutic strategies highlights their growing potential as ...
Md Sifat Rahi, Md Mijanur Rahman, Asma Talukder, Urooj Yousaf Virk, Jennifer C. Wilson, Nigel McMillan, Ming Q. Wei   +6 more
wiley   +1 more source

In situ PCR for Mycobacterium tuberculosis in endoscopic mucosal biopsy specimens of intestinal tuberculosis and Crohn disease [PDF]

, 2008
Tuberculosis and Crohn disease are granulomatous disorders affecting the intestinal tract with similar clinical manifestations and pathologic features.
Pulimood, AB, Rook, GWA, Peter, S, Donoghue, HD   +3 more
core  

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source